Choose your preferred way to stay informed of new case launches and settlement deadlines
On July 30, 2024, PepGen released data from its ongoing Phase 2 trial of its drug candidate PGN-EDO51. On this news, PepGen stock fell over 45% during intraday trading on July 31, 2024.
In order to be eligible to join the PEPG class action lawsuit, you must have incurred a loss on shares of PepGen purchased during the class period listed above.
TOP
